Tezepelumab reduces mucus plugging in patients with uncontrolled, moderate-to-severe asthma: the phase 2 CASCADE study
L. H Nordenmark (Oslo, Norway), C. Emson (Gaithersburg, MD, United States), Å. Hellqvist (Gothenburg, Sweden), J. Johnston (Cambridge, United Kingdom), H. Greberg (Gothenburg, Sweden), J. Griffiths (Gaithersburg, MD, United States), J. Newell Jr (Iowa, United States), J. Parnes (California, United States), G. Colice (Gaithersburg, MD, United States), C. Brightling (Leicester, United Kingdom)
Source: International Congress 2022 – ALERT 4: Asthma and interventional pulmonology
Session: ALERT 4: Asthma and interventional pulmonology
Session type: Clinical trials session
Number: 4445
  
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
L. H Nordenmark (Oslo, Norway), C. Emson (Gaithersburg, MD, United States), Å. Hellqvist (Gothenburg, Sweden), J. Johnston (Cambridge, United Kingdom), H. Greberg (Gothenburg, Sweden), J. Griffiths (Gaithersburg, MD, United States), J. Newell Jr (Iowa, United States), J. Parnes (California, United States), G. Colice (Gaithersburg, MD, United States), C. Brightling (Leicester, United Kingdom). Tezepelumab reduces mucus plugging in patients with uncontrolled, moderate-to-severe asthma: the phase 2 CASCADE study. 4445
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|